Cargando…
In Vivo Efficacy of SQ109 against Leishmania donovani, Trypanosoma spp. and Toxoplasma gondii and In Vitro Activity of SQ109 Metabolites
SQ109 is an anti-tubercular drug candidate that has completed Phase IIb/III clinical trials for tuberculosis and has also been shown to exhibit potent in vitro efficacy against protozoan parasites including Leishmania and Trypanosoma cruzi spp. However, its in vivo efficacy against protozoa has not...
Autores principales: | Baek, Kyung-Hwa, Phan, Trong-Nhat, Malwal, Satish R., Lee, Hyeryon, Li, Zhu-Hong, Moreno, Silvia N. J., Oldfield, Eric, No, Joo Hwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944987/ https://www.ncbi.nlm.nih.gov/pubmed/35327472 http://dx.doi.org/10.3390/biomedicines10030670 |
Ejemplares similares
-
In Vitro Characterization of the Anti-Bacterial Activity of SQ109 against Helicobacter pylori
por: Makobongo, Morris O., et al.
Publicado: (2013) -
Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450
por: Bukhdruker, Sergey, et al.
Publicado: (2020) -
Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits
por: Egbelowo, Oluwaseun, et al.
Publicado: (2021) -
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
por: Boeree, Martin J, et al.
Publicado: (2017) -
Inhibition Mechanism of Anti-TB Drug SQ109: Allosteric
Inhibition of TMM Translocation of Mycobacterium Tuberculosis MmpL3
Transporter
por: Carbone, Justin, et al.
Publicado: (2023)